Clinical trial
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory…
NCT00278343 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00278343 |
|---|---|
| Title | Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer |
| Official title | A Phase 2 Study of AZD2171 in Recurrent or Persistent Ovarian, Peritoneal, or Fallopian Tube Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer |
| Intervention type | Drug, Other |
| Interventions | cediranib maleate, laboratory biomarker analysis |
| Enrollment | 74 |
| Start date | Apr 1, 2006 |
| Primary completion | Jun 1, 2010 |
| Completion | Jan 15, 2018 |
| First posted | Jan 18, 2006 |
| Last update posted | Aug 29, 2018 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: